OBJECTIVE: To examine the epidemiology of gout and gout treatment in the United Kingdom using a large national practice based population. METHODS: Data from the UK General Practice Research Database from 1990 to 1999 were examined. Physician diagnoses and drug codes were used, and trends in gout incidence and treatment examined. Additionally, disease prevalence for the year 1999 was assessed. To examine the association of gout with comorbid disease, the prevalence of select health conditions and drug use was compared with the corresponding prevalences seen in osteoarthritis, adjusting for both age and sex. RESULTS: From 1 January 1990 to 31 December 1999 overall gout incidence remained relatively stable, ranging from a low of 11.9 cases (95% confidence interval (CI) 11.5 to 12.3) in 1991 to a high of 18.0 cases (95% CI 17.6 to 18.4) per 10 000 patient-years in 1994. Gout prevalence in 1999 was 1.4% with rates approaching 7% in men over the age of 65. Drugs used for the treatment of gout remained constant in prevalent cases with the exception of a significant decline in non-steroidal anti-inflammatory drug use over the 10 year follow up. Compared with patients with osteoarthritis, patients with gout were significantly more likely to have cardiovascular disease, hypertension, diabetes, and chronic renal failure, and were more likely to have used diuretics or ciclosporin, or both. CONCLUSION: Although gout is common in the UK, particularly among older men, the incidence of the disease seems to have remained stable during the 1990s.
OBJECTIVE: To examine the epidemiology of gout and gout treatment in the United Kingdom using a large national practice based population. METHODS: Data from the UK General Practice Research Database from 1990 to 1999 were examined. Physician diagnoses and drug codes were used, and trends in gout incidence and treatment examined. Additionally, disease prevalence for the year 1999 was assessed. To examine the association of gout with comorbid disease, the prevalence of select health conditions and drug use was compared with the corresponding prevalences seen in osteoarthritis, adjusting for both age and sex. RESULTS: From 1 January 1990 to 31 December 1999 overall gout incidence remained relatively stable, ranging from a low of 11.9 cases (95% confidence interval (CI) 11.5 to 12.3) in 1991 to a high of 18.0 cases (95% CI 17.6 to 18.4) per 10 000 patient-years in 1994. Gout prevalence in 1999 was 1.4% with rates approaching 7% in men over the age of 65. Drugs used for the treatment of gout remained constant in prevalent cases with the exception of a significant decline in non-steroidal anti-inflammatory drug use over the 10 year follow up. Compared with patients with osteoarthritis, patients with gout were significantly more likely to have cardiovascular disease, hypertension, diabetes, and chronic renal failure, and were more likely to have used diuretics or ciclosporin, or both. CONCLUSION: Although gout is common in the UK, particularly among older men, the incidence of the disease seems to have remained stable during the 1990s.
Authors: Emvalee Arromdee; Clement J Michet; Cynthia S Crowson; W Michael O'Fallon; Sherine E Gabriel Journal: J Rheumatol Date: 2002-11 Impact factor: 4.666
Authors: M H Chin; L C Wang; L Jin; R Mulliken; J Walter; D C Hayley; T G Karrison; M P Nerney; A Miller; P D Friedmann Journal: Acad Emerg Med Date: 1999-12 Impact factor: 3.451
Authors: Patrick Sulem; Daniel F Gudbjartsson; G Bragi Walters; Hafdis T Helgadottir; Agnar Helgason; Sigurjon A Gudjonsson; Carlo Zanon; Soren Besenbacher; Gyda Bjornsdottir; Olafur T Magnusson; Gisli Magnusson; Eirikur Hjartarson; Jona Saemundsdottir; Arnaldur Gylfason; Adalbjorg Jonasdottir; Hilma Holm; Ari Karason; Thorunn Rafnar; Hreinn Stefansson; Ole A Andreassen; Jesper H Pedersen; Allan I Pack; Marieke C H de Visser; Lambertus A Kiemeney; Arni J Geirsson; Gudmundur I Eyjolfsson; Isleifur Olafsson; Augustine Kong; Gisli Masson; Helgi Jonsson; Unnur Thorsteinsdottir; Ingileif Jonsdottir; Kari Stefansson Journal: Nat Genet Date: 2011-10-09 Impact factor: 38.330
Authors: Eric Jutkowitz; Fernando Alarid-Escudero; Hyon K Choi; Karen M Kuntz; Hawre Jalal Journal: Pharmacoeconomics Date: 2017-10 Impact factor: 4.981